AML (ACUTE MYELOID LEUKEMIA)
Clinical trials for AML (ACUTE MYELOID LEUKEMIA) explained in plain language.
Never miss a new study
Get alerted when new AML (ACUTE MYELOID LEUKEMIA) trials appear
Sign up with your email to follow new studies for AML (ACUTE MYELOID LEUKEMIA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental CAR-T therapy targets tough childhood leukemia
Disease control Not yet recruitingThis early-phase study tests a new treatment called CLL-1 CAR-T for children aged 3 to 18 with acute myeloid leukemia (AML) that has returned or not responded to standard therapy. The therapy uses the patient's own immune cells, modified to recognize and attack leukemia cells. Th…
Matched conditions: AML (ACUTE MYELOID LEUKEMIA)
Phase: EARLY_PHASE1 • Sponsor: First Affiliated Hospital of Guangxi Medical University • Aim: Disease control
Last updated May 17, 2026 02:46 UTC
-
Double punch against leukemia: CAR-T cells then stem cell transplant
Disease control Not yet recruitingThis study tests a two-step treatment for people with acute myeloid leukemia (AML) that has come back or not responded to standard chemo. First, patients receive specially engineered immune cells (CLL1 CAR-T) to attack the cancer. Then, they get a stem cell transplant from a heal…
Matched conditions: AML (ACUTE MYELOID LEUKEMIA)
Phase: NA • Sponsor: Donghua Zhang • Aim: Disease control
Last updated May 17, 2026 02:46 UTC
-
New immune-boosting transplant aims to stop leukemia relapse
Disease control Not yet recruitingThis study tests a stem cell transplant from a matched sibling donor combined with special immune cells (regulatory and conventional T cells) for people with high-risk acute myeloid leukemia (AML). The goal is to prevent the cancer from coming back after the transplant. About 28 …
Matched conditions: AML (ACUTE MYELOID LEUKEMIA)
Phase: PHASE2 • Sponsor: Antonio Pierini • Aim: Disease control
Last updated May 17, 2026 02:46 UTC
-
Double CAR-T attack on tough leukemia: early trial opens
Disease control Not yet recruitingThis early-phase trial tests a two-step CAR-T cell therapy for people with relapsed or refractory acute myeloid leukemia (AML), a type of blood cancer that has not responded to standard treatments. Ten participants will receive an infusion of dual-target CAR-T cells followed by a…
Matched conditions: AML (ACUTE MYELOID LEUKEMIA)
Phase: EARLY_PHASE1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 17, 2026 02:43 UTC
-
New hope for AML patients too weak for harsh chemo: gentler drug combo aims to rapidly clear cancer cells
Disease control Not yet recruitingThis study tests a new drug combination using selinexor with reduced or no standard chemotherapy for adults with newly diagnosed AML who cannot tolerate intensive treatment. The goal is to quickly lower the number of leukemia cells in the blood while causing fewer side effects. A…
Matched conditions: AML (ACUTE MYELOID LEUKEMIA)
Phase: NA • Sponsor: Donghua Zhang • Aim: Disease control
Last updated May 17, 2026 02:40 UTC
-
New hope for AML patients: targeted combo challenges standard chemo
Disease control Not yet recruitingThis study compares a new three-drug combination (gilteritinib, azacitidine, and venetoclax) to standard intensive chemotherapy for adults newly diagnosed with a specific genetic subtype of acute myeloid leukemia (FLT3-ITD). About 230 participants aged 18 to 75 will be randomly a…
Matched conditions: AML (ACUTE MYELOID LEUKEMIA)
Phase: PHASE2, PHASE3 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
Engineered immune cells take aim at Hard-to-Treat blood cancers
Disease control Not yet recruitingThis early-phase study tests a new treatment called CD64 CAR T cells for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) that have come back or not responded to standard therapy. The treatment involves taking a patient's own immune cells, mod…
Matched conditions: AML (ACUTE MYELOID LEUKEMIA)
Phase: PHASE1 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New chemo combo could boost stem cell transplant success for leukemia patients
Disease control Not yet recruitingThis study tests which of two chemotherapy drugs, treosulfan or melphalan, works better and causes fewer side effects when given before a stem cell transplant for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). About 220 adults who are already schedule…
Matched conditions: AML (ACUTE MYELOID LEUKEMIA)
Phase: PHASE2 • Sponsor: Technische Universität Dresden • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Engineered immune cells take on tough leukemia
Disease control Not yet recruitingThis early-phase trial tests a new type of CAR-T cell therapy for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to better find and attack leukemia cells. The study aims …
Matched conditions: AML (ACUTE MYELOID LEUKEMIA)
Phase: PHASE1, PHASE2 • Sponsor: Xuzhou Medical University • Aim: Disease control
Last updated May 13, 2026 15:58 UTC
-
New drug combo may boost stem cell transplant success in hard-to-treat blood cancers
Disease control Not yet recruitingThis study tests whether adding venetoclax to the usual pre-transplant chemotherapy (treosulfan) can safely improve survival for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). About 27 adults aged 18–75 will receive this stronger conditionin…
Matched conditions: AML (ACUTE MYELOID LEUKEMIA)
Phase: PHASE2 • Sponsor: University Hospital Tuebingen • Aim: Disease control
Last updated May 01, 2026 15:59 UTC